Compare Autodesk Inc (ADSK) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Autodesk Inc vs Merck & Co., Inc. — how do they compare? Autodesk Inc trades at $206.52 (market cap $44.84B), while Merck & Co., Inc. trades at $126.1 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 7.1× Autodesk Inc's market cap, and Merck & Co., Inc. pays a 2.64% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | MRK | |
|---|---|---|
Market Cap | $44.84B | $318.26B |
Sector | Technology | Health |
52-Week High | $326.79 | $129.52 |
52-Week Low | $187.72 | $77.60 |
Enterprise Value | $44.64B | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.
Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.
Merck (MRK) trades at $125.99, down 0.62% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected. Revenue grew to $65.01B in 2025, and net income reached $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, driven by earnings momentum, strategic acquisitions, and strong institutional interest. Risks include rising debt levels and competitive pressures in the pharma sector. With a consensus price target of $139.33, representing ~11% upside, the stock offers growth potential but requires monitoring of execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
